Flanvotumab

• CAT Number: I042100
• CAS Number: 1188277-05-5
• Purity: ≥95%

Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance[1].
Flanvotumab is based on TA99, a murine IgG2a anti-TYRP1 mAb, localizes to subcutaneous melanoma xenografts and inhibits syngeneic tumor growth in preclinical models[1].
TA99 exhibits antitumor effect depending on the intact antibody, the presence of Fc receptor, and natural killer (NK) cells[1].

Reference

[1]. Khalil DN, et al. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 1;22(21):5204-5210.
 [Content Brief]